tuneTypical Dose
300-500 mg/day EGCG in 1-2 doses with meals.
Supplement
Epigallocatechin Gallate
Epigallocatechin Gallate
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Typical onset is assessed over 1-4 weeks. Clearer signals often emerge by 4-12 weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Epigallocatechin Gallate is a plant derived polyphenol or pigment found in many fruits and herbs. It is used for antioxidant support and cardiometabolic research.
Controlled trials with polyphenol rich preparations sometimes show modest improvements in endothelial function, oxidative stress biomarkers, or postprandial glucose. Effects are inconsistent because dose and bioavailability vary. Minority literature explores neuroprotection, skin photoprotection, and microbiome modulation, with evidence mostly preclinical or from small human studies.
Modulation of signaling pathways implicated in the target symptom domain.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- PMID 41683770 and 41683202 show modest improvements in selected cardiometabolic endpoints
- PMID 41534183 and 41300526 show heterogeneous pooled effects and lower certainty for broad cognition or performance claims
Secondary Outcomes
- At moderate oral dosing with meals, PMIDs 41683770 and 41683202 report mostly acceptable tolerability
- PMID 41534183 and 41300526 indicate response varies by catechin composition and baseline phenotype
Safety
Contraindications and Interactions
Contraindications
- Known allergy to source material
- Unstable psychiatric states
- Advanced liver/kidney disease
Side effects
- Gastrointestinal discomfort
- Headache
- Transient fatigue or stimulation depending on formulation
Interactions
- Sedatives, stimulants, and blood-pressure- or anticoagulant-active medications
- Overlapping botanicals with similar mechanism burden
- Multi-ingredient stacks without washout
Avoid if
- Unmonitored pregnancy/lactation
- Severe liver/renal injury
- Recent cardiovascular instability
Evidence
Study-level References
epigallocatechin-gallate-SRC-001Human clinical evidence (PMID: 41683770; PMID: 41683202)
Sourceopen_in_newPMID: 41683770,41683202
Population: Adults in condition-specific settings
Dose protocol: Oral EGCG or green-tea catechin interventions with dose-specific regimens
Key findings: Modest, context-specific effects
Notes: Small sample sizes, short durations, and nonstandardized endpoints
Paper content
Modest, context-specific effects
epigallocatechin-gallate-SRC-002Human evidence synthesis (PMID: 41534183; PMID: 41300526)
Sourceopen_in_newPMID: 41534183,41300526
Population: Adult cohorts across variable indications
Dose protocol: Mixed products/doses
Key findings: Heterogeneous or inconsistent pooled outcomes
Notes: Publication and comparability limitations
Paper content
Heterogeneous or inconsistent pooled outcomes
epigallocatechin-gallate-SRC-003Meta-analysis of randomized controlled trials.
Sourceopen_in_newYildirim Ayaz E, Dincer B, Mesci B. Effect of Green Tea on Blood Pressure in Healthy Individuals: A Meta-Analysis. Altern Ther Health Med. 2023;29(5):66-73. PMID:36689359.
Population: Healthy adults from 9 randomized controlled trials.
Dose protocol: Green tea or EGCG supplementation across 9 RCTs (680 participants)
Key findings: Systolic BP reduced by 2.99 mmHg and diastolic BP by 0.95 mmHg in healthy individuals.
Notes: Meta-analysis with no detected publication bias. Consistent modest effect on blood pressure.
Paper content
This meta-analysis pooled 9 RCTs with 680 healthy participants to examine the effect of green tea supplementation on blood pressure. Green tea reduced systolic blood pressure by 2.99 mmHg and diastolic blood pressure by 0.95 mmHg compared to control. No publication bias was detected, and study completion rates ranged from 85-100%. The findings support a modest but consistent blood pressure lowering effect of green tea catechins (primarily EGCG) in healthy individuals, adding to the cardiometabolic evidence base for this compound.